Becton Dickinson and Co
NYSE:BDX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
165.15
249.08
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BDX
stock under the Base Case scenario is
273.52
USD.
Compared to the current market price of 193.76 USD,
Becton Dickinson and Co
is
Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Becton Dickinson and Co.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Heavy reliance on higher-margin hospital consumables leaves BD vulnerable to increasing cost pressures and potential manufacturing capacity constraints, which could compress margins if supply chain challenges persist.
The company’s sizable M&A-driven growth strategy, highlighted by its acquisition of C. R. Bard, may lead to integration challenges and divert management’s focus away from organic product innovation, dampening long-term competitiveness.
Growing regulatory scrutiny over infection-prevention protocols and device safety could lead to higher compliance costs and longer product approval timelines, particularly for BD’s advanced infusion and surgical solutions.
BD’s entrenched leadership in core medical device categories, including syringes and infusion systems, provides stable demand and strong pricing power in an essential, non-discretionary market.
Its significant R&D investments in advanced diagnostic tools and biosafety solutions position BD to capture emerging growth opportunities, especially as healthcare systems increasingly value infection prevention technologies.
A broad global footprint and established distribution networks protect BD against regional shocks, while continued expansion in emerging markets offers both long-term volume growth and the chance to deepen customer relationships.
Revenue & Expenses Breakdown
Becton Dickinson and Co
Balance Sheet Decomposition
Becton Dickinson and Co
| Current Assets | 9.3B |
| Cash & Short-Term Investments | 649m |
| Receivables | 3B |
| Other Current Assets | 5.6B |
| Non-Current Assets | 46.1B |
| PP&E | 7B |
| Intangibles | 36B |
| Other Non-Current Assets | 3.1B |
| Current Liabilities | 8.3B |
| Other Current Liabilities | 8.3B |
| Non-Current Liabilities | 21.6B |
| Long-Term Debt | 17.6B |
| Other Non-Current Liabilities | 4B |
Free Cash Flow Analysis
Becton Dickinson and Co
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Becton Dickinson and Co
|
Revenue
|
21.8B
USD
|
|
Cost of Revenue
|
-11.9B
USD
|
|
Gross Profit
|
9.9B
USD
|
|
Operating Expenses
|
-6.9B
USD
|
|
Operating Income
|
3B
USD
|
|
Other Expenses
|
-1.3B
USD
|
|
Net Income
|
1.7B
USD
|
BDX Profitability Score
Profitability Due Diligence
Becton Dickinson and Co's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Becton Dickinson and Co's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
BDX Solvency Score
Solvency Due Diligence
Becton Dickinson and Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Becton Dickinson and Co's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDX Price Targets Summary
Becton Dickinson and Co
According to Wall Street analysts, the average 1-year price target for
BDX
is 209.55 USD
with a low forecast of 184.83 USD and a high forecast of 295.58 USD.
Dividends
Current shareholder yield for
BDX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BDX
stock under the Base Case scenario is
273.52
USD.
Compared to the current market price of 193.76 USD,
Becton Dickinson and Co
is
Undervalued by 29%.